| 1.13 -0.02 (-1.74%) | 02-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.54 |
1-year : | 1.74 |
| Resists | First : | 1.32 |
Second : | 1.49 |
| Pivot price | 1.13 |
|||
| Supports | First : | 1.04 | Second : | 0.87 |
| MAs | MA(5) : | 1.13 |
MA(20) : | 1.13 |
| MA(100) : | 1.17 |
MA(250) : | 1.52 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 40.9 | D(3) : | 40.4 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 2.71 | Low : | 0.81 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IRD ] has closed above bottom band by 43.9%. Bollinger Bands are 53.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.16 - 1.17 | 1.17 - 1.17 |
| Low: | 1.09 - 1.09 | 1.09 - 1.1 |
| Close: | 1.12 - 1.13 | 1.13 - 1.14 |
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Sat, 08 Feb 2025
Opus Genetics revises executive compensation agreements - MSN
Fri, 20 Dec 2024
Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com
Thu, 19 Dec 2024
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy - Yahoo Finance
Tue, 03 Dec 2024
Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a - GlobeNewswire
Tue, 12 Nov 2024
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 32 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 16.1 (%) |
| Held by Institutions | 8.1 (%) |
| Shares Short | 665 (K) |
| Shares Short P.Month | 835 (K) |
| EPS | -1.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.3 |
| Profit Margin | 0 % |
| Operating Margin | -207.2 % |
| Return on Assets (ttm) | -39 % |
| Return on Equity (ttm) | -64.4 % |
| Qtrly Rev. Growth | -67.6 % |
| Gross Profit (p.s.) | -0.17 |
| Sales Per Share | 0.26 |
| EBITDA (p.s.) | -0.94 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -1.04 |
| PEG Ratio | 0 |
| Price to Book value | 0.86 |
| Price to Sales | 4.25 |
| Price to Cash Flow | -2.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|